Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31350661 | 0.81 | CA14 (0.39) | CA14CA12ALDH1A1MEN1KMT2A | |
| SCHEMBL2626596 | 0.81 | CA14 (0.39) | CA14CA12ALDH1A1MEN1KMT2A | |
| SCHEMBL25414730 | 0.80 | CA14 (0.34) | CA14CA12ALDH1A1 | |
| SCHEMBL2327528 | 0.77 | CA1 (0.38) | CA14CA12ALDH1A1MEN1KMT2A | |
| SCHEMBL12932471 | 0.77 | CA1 (0.38) | CA14CA12ALDH1A1MEN1KMT2A | |
| SCHEMBL8894673 | 0.76 | SMN1; SMN2 (0.42) | CA14ALDH1A1SLC1A1 | |
| SCHEMBL10012900 | 0.74 | CA14 (0.35) | CA14CA12ALDH1A1 | |
| SCHEMBL31289858 | 0.73 | USP2 (0.40) | CA14CA12ALDH1A1PMP22CASR | |
| SCHEMBL19395796 | 0.73 | CA14 (0.34) | CA14CA12ALDH1A1 | |
| SCHEMBL16943968 | 0.72 | CA14 (0.36) | CA14CA12ALDH1A1PMP22CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961246-B2 | 18F-labelled folates as PET radiotracers | Merck & Cie (CH) | 2021-03-30 | — | — | US | disclosed |
| US-20180072734-A1 | 18F-LABELLED FOLATES AS PET RADIOTRACERS | Merck & Cie (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072734-A1 | 18F-LABELLED FOLATES AS PET RADIOTRACERS | FOLR1, FOLR2, SLC19A1 | CA14 386/4885CA12 600/4885ALDH1A1 720/4885 |
| US-10961246-B2 | 18F-labelled folates as PET radiotracers | FOLR1, FOLR2, SLC19A1 | CA14 386/4885CA12 600/4885ALDH1A1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.